JPRN-UMIN000001530已完成未知
Phase II trial of capecitabine for brain metastasis of breast cancer - Capecitabine-brain meta
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •The patient have not indication for capecitabine therapy
研究者
相似试验
已完成
2 期
Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) PatientsMetastatic Renal Cell CarcinomaNCT01182142Kidney Cancer Research Bureau51
进行中（未招募）
不适用
Prospective phase II trial using Capecitabine and Trastuzumab for therapy of female patients with cerebral metastasizing, HER2-overexpressing breast cancer - HERXECNS-metastasizing HER2-overexpressing breast cancerMedDRA version: 9.1Level: PTClassification code 10057654Term: Breast cancer femaleMedDRA version: 9.1Level: PTClassification code 10006202Term: Breast cancer stage IVEUCTR2007-003634-42-DEKlinikum der Universität München, Standort Großhadern
进行中（未招募）
1 期
A Phase II Study of Lapatinib for Brain Metastases in Subjectswith ErbB2-Positive Breast Cancer Following Trastuzumab basedSystemic Therapy and Cranial RadiotherapyProgressive symptomatic or asymptomatic ErbB2 overexpressing breast cancer brain metastases.EUCTR2005-003944-68-GRGlaxoSmithKline R&D Ltd220
进行中（未招募）
1 期
A Phase II Study of Lapatinib for Brain Metastases in Subjectswith ErbB2-Positive Breast Cancer Following Trastuzumab basedSystemic Therapy and Cranial RadiotherapyProgressive symptomatic or asymptomatic ErbB2 overexpressing breast cancer brain metastases.EUCTR2005-003944-68-BEGlaxoSmithKline R&D Ltd220
进行中（未招募）
1 期
A Study of Lapatinib for Brain Metastases in Subjects with ErbB2-PositiveBreast Cancer Following Trastuzumab Therapy and Cranial RadiotherapyEUCTR2005-003944-68-GBovartis Pharma Services AG220